Institution
Hebron University
Education•Hebron, Palestinian Territory•
About: Hebron University is a education organization based out in Hebron, Palestinian Territory. It is known for research contribution in the topics: Population & Cancer. The organization has 2714 authors who have published 4180 publications receiving 163736 citations.
Topics: Population, Cancer, Breast cancer, Medicine, Metastatic breast cancer
Papers published on a yearly basis
Papers
More filters
TL;DR: It was demonstrated that pazopanib maintenance therapy significantly increased progression-free survival (PFS) in patients with ovarian cancer whose disease had not progressed after first-line therapy.
46 citations
TL;DR: Findings in MCRC have also been confirmed in a large phase III trial in early stage colon cancer (X-Act adjuvant study) and phase II clinical trials in metastatic breast cancer and nurses will be assuming a more significant and pivotal role in the efficient education and support of patients during home-based therapy with capecitabine.
46 citations
École Polytechnique Fédérale de Lausanne1, University of Auvergne2, Aix-Marseille University3, University of Cambridge4, Ikerbasque5, Hebron University6, Cornell University7, Memorial Sloan Kettering Cancer Center8, Catalan Institution for Research and Advanced Studies9, University of the Basque Country10
TL;DR: It is shown that PML is a novel target in aggressive breast cancer, and a novel pathway sustaining breast cancer aggressiveness that can be therapeutically exploited in combination with PML-based stratification is identified.
Abstract: Patient stratification has been instrumental for the success of targeted therapies in breast cancer. However, the molecular basis of metastatic breast cancer and its therapeutic vulnerabilities remain poorly understood. Here we show that PML is a novel target in aggressive breast cancer. The acquisition of aggressiveness and metastatic features in breast tumours is accompanied by the elevated PML expression and enhanced sensitivity to its inhibition. Interestingly, we find that STAT3 is responsible, at least in part, for the transcriptional upregulation of PML in breast cancer. Moreover, PML targeting hampers breast cancer initiation and metastatic seeding. Mechanistically, this biological activity relies on the regulation of the stem cell gene SOX9 through interaction of PML with its promoter region. Altogether, we identify a novel pathway sustaining breast cancer aggressiveness that can be therapeutically exploited in combination with PML-based stratification.
46 citations
TL;DR: An electrochemical point-of-care device for the fast, simple and quantitative detection of Plasmodiumfalciparum lactate dehydrogenase (PfLDH) in whole blood samples is reported.
46 citations
TL;DR: The single-arm OCTAVIA study evaluated front-line bevacizumab plus weekly paclitaxel and q3w carboplatin in newly diagnosed ovarian cancer patients, demonstrating median progression-free survival (PFS) of approximately 2 years.
46 citations
Authors
Showing all 2723 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| José Baselga | 156 | 707 | 122498 |
| M. I. Martínez | 134 | 1251 | 79885 |
| Josep Tabernero | 111 | 803 | 68982 |
| Jordi Rello | 103 | 694 | 35994 |
| Xavier Montalban | 95 | 762 | 52842 |
| James M. Downey | 91 | 381 | 29506 |
| Enriqueta Felip | 83 | 622 | 53364 |
| Joaquim Bellmunt | 82 | 660 | 41472 |
| Joan Montaner | 80 | 489 | 22413 |
| Marc Miravitlles | 76 | 651 | 25671 |
| David H. Salat | 75 | 241 | 36779 |
| Eduard Gratacós | 75 | 531 | 20178 |
| Alex Rovira | 74 | 356 | 19586 |
| Ramon Bataller | 72 | 283 | 19316 |
| Maria Buti | 71 | 493 | 26596 |